Jump to Main Content
Avian Influenza Mucosal Vaccination in Chickens with Replication-Defective Recombinant Adenovirus Vaccine
- Toro, Haroldo, Suarez, David L., Tang, De-chu C., van Ginkel, Frederik W., Breedlove, Cassandra
- Avian diseases 2011 v.55 no.1 pp. 43
- Adenoviridae, RNA, antibodies, avian influenza, chickens, genes, hemagglutination, mucosal immunity, recombinant vaccines, vaccination, viruses
- We evaluated protection conferred by mucosal vaccination with replication-competent adenovirus-free recombinant adenovirus expressing a codon-optimized avian influenza (AI) H5 gene from A/turkey/WI/68 (AdTW68.H5ck). Commercial, layertype chicken groups were either singly vaccinated ocularly at 5 days of age, singly vaccinated via spray at 5 days of age, or ocularly primed at 5 days and ocularly boosted at 15 days of age. Only chickens primed and boosted via the ocular route developed AI systemic antibodies with maximum hemagglutination inhibition mean titers of 3.9 log2 at 32 days of age. In contrast, single vaccination via the ocular or spray routes maintained an antibody status similar to unvaccinated controls. All chickens (16/16) subjected to ocular priming and boosting with AdTW68.H5ck survived challenge with highly pathogenic AI virus A/chicken/Queretaro/14588-19/95 (H5N2). Single ocular vaccination resulted in 63% (10/16) of birds surviving the challenge followed by a 44% (7/16) survival of single-sprayed vaccinated birds. Birds vaccinated twice via the ocular route also showed significantly lower (P , 0.05) AI virus RNA concentrations in oropharyngeal swabs compared to unvaccinated–challenged controls.